Akatinol Memantine, 20 mg 56 pcs.

Pharmacodynamics

As a non-competitive antagonist of N-methyl-D-aspartate (NMDA)-receptors it has modulatory effect on glutamatergic system. It regulates ion transport, blocks calcium channels, normalizes membrane potential, improves nerve impulse transmission. Improves cognitive processes, increases daily activity.

Pharmacokinetics

Akatinol Memantine is quickly and completely absorbed after oral administration. Maximum plasma concentration is reached within 2-6 hours. No cumulation of the drug is noted in normal renal function. Excretion is biphasic. Period of semiejection half-life is 4-9 hours in the first phase, and 40-65 hours in the second phase.
It is excreted in the urine.

Indications

Alzheimer’s disease, Consequences of stroke, Acquired dementia, Attention and memory disorders, Concussion and other brain injuries, Alcoholism

Alzheimer’s type dementia, vascular dementia, mixed dementia of all degrees of severity.

.

Active ingredient

Memantine

Composition

Active ingredient:

Memantine hydrochloride;

Associates:

Lactose;

MCC;

Colloidal silicon dioxide;

Talc;

Magnesium stearate:

methacrylic acid copolymer;

sodium lauryl sulfate;

polysorbate 80;

triacetin;

simethicone emulsion;

talt.

How to take, the dosage

Akatinol Memantine is taken orally, with meals. Dosing regimen is set individually. It is recommended to start treatment with prescription of the lowest effective dose.

In adults with dementia during the 1st week of therapy – in a dose of 5 mg/day, the 2nd week – in a dose of 10 mg/day, the 3rd week – in a dose of 15-20 mg/day. If necessary, further weekly dose increase by 10 mg to reach a daily dose of 30 mg.

The optimal dose is reached gradually, increasing the dose each week.

Interaction

Concomitant use with barbiturates, neuroleptics, anticholinergic agents may increase the effect of the latter. When concomitant use may change (increase or decrease) the effect of dantrolene or baclofen, so the doses of the drugs should be adjusted individually.

.

Special Instructions

Patients with moderate to severe dementia with Alzheimer’s disease usually have impaired ability to drive vehicles and operate complex machinery.

In addition, memantine may cause changes in reaction speed, so patients treated as outpatients should use extra caution when driving or operating machinery.

Contraindications

• individual hypersensitivity to the drug Akatinol Memantine;
• explicit renal dysfunction;
• pregnancy;
• breastfeeding;
• children under 18 years of age (due to insufficient data).
  • With caution:
• thyrotoxicosis;
  • epilepsy;
  • convulsions (incl.
  • cancer (including history);
  • myocardial infarction;
• cardiac insufficiency.

Side effects

The adverse reactions are classified according to clinical manifestations (according to the affected organ systems) and frequency of occurrence: Very common – ≥1/10; common – ≥1/100-

General adverse reactionsRarelyHeadacheRarelyTirednessInfectionsRarelyFungal infectionsPsychiatric disordersFrequentlySleepinessRarely Confusion of consciousnessRarelyHallucinations1Frequency not determinedPsychotic reactions2Cardiovascular disordersVascular SystemRarelyHypertensionRarelyVenous Thrombosis/ThromboembolismGastrointestinal DisordersFrequentlyIngestionRarelyNausea, VomitingFrequency not determinedPancreatitis2Nervous system disordersRarelyDizzinessRarelyGait disorderVery rareCramp

Prevalence/p>

1Hallucinations have been observed mainly in patients with Alzheimer’s disease at the stage of severe dementia.

2There have been anecdotal reports of these adverse reactions with clinical use of the drug (data obtained after the drug was commercially available).

Overdose

Symptoms: increased severity of side effects.

Treatment: gastric lavage, administration of activated charcoal, symptomatic therapy.

.

Similarities

Noogeron, Maruksa, Memantal, Memaneirin, Memantine